AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

RecruitingPhase 2Ages 18 Years - anyAllMerck Sharp & Dohme LLC
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of care systemic treatment * Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active central nervous system metastases and/or carcinomatous meningitis and/or primary brain tumors * Has active infection, other than those permitted per protocol, requiring systemic therapy * Has not adequately recovered from major surgery or has ongoing surgical complications
๐Ÿ’Š

What it tests

  • Calderasib
  • Cetuximab
๐Ÿ“

Where

72 sites
Greater Baltimore Medical Center ( Site 1104)
Baltimore, United States
START Midwest ( Site 1103)
Grand Rapids, United States
Comprehensive Cancer Centers of Nevada ( Site 1109)
Las Vegas, United States
Rutgers Cancer Institute of New Jersey ( Site 1100)
New Brunswick, United States
START Mountain Region ( Site 1106)
West Valley City, United States
Virginia Cancer Specialists ( Site 1102)
Fairfax, United States
Prince of Wales Hospital-Medical Oncology ( Site 1003)
Randwick, Australia
Westmead Hospital ( Site 1000)
Westmead, Australia

โ€ฆand 64 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy